Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in <i>EGFR</i>-Mutant Non-small Cell Lung Cancer.

Shaurova, Tatiana; Zhang, Letian; Goodrich, David W; Hershberger, Pamela A

Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer.

Shaurova, Tatiana; Zhang, Letian; Goodrich, David W; Hershberger, Pamela A.

Afiliación

Shaurova T; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
Zhang L; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
Goodrich DW; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
Hershberger PA; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.

Front Genet ; 11: 281, 2020.

Article en En | MEDLINE | ID: mdl-32292420

Palabras clave

EGFR mutant lung cancer; EGFR tyrosine kinase inhibitors; Rb1; acquired resistance; epithelial-mesenchymal transition; lineage plasticity; neuroendocrine transformation

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Front Genet Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Front Genet Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos